Foundry Partners LLC Purchases Shares of 1,135 Repligen Co. (NASDAQ:RGEN)

Foundry Partners LLC purchased a new position in shares of Repligen Co. (NASDAQ:RGEN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,135 shares of the biotechnology company’s stock, valued at approximately $204,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Artisan Partners Limited Partnership raised its stake in Repligen by 11.3% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock worth $247,558,000 after acquiring an additional 157,807 shares during the last quarter. Wellington Management Group LLP raised its position in Repligen by 2.1% during the 3rd quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company’s stock worth $222,075,000 after buying an additional 29,215 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Repligen by 13.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock valued at $190,117,000 after acquiring an additional 137,220 shares during the period. Conestoga Capital Advisors LLC boosted its position in Repligen by 0.4% during the fourth quarter. Conestoga Capital Advisors LLC now owns 709,738 shares of the biotechnology company’s stock worth $127,611,000 after purchasing an additional 2,590 shares in the last quarter. Finally, Parnassus Investments LLC acquired a new stake in shares of Repligen in the third quarter valued at approximately $87,475,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Repligen

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now owns 24,260 shares in the company, valued at approximately $4,699,889.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. Insiders sold 25,597 shares of company stock valued at $5,039,532 in the last 90 days. 1.20% of the stock is currently owned by insiders.

Repligen Trading Up 8.8 %

NASDAQ:RGEN opened at $171.28 on Wednesday. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. The firm has a market cap of $9.56 billion, a P/E ratio of 237.89, a PEG ratio of 5.16 and a beta of 1.02. The stock’s 50 day simple moving average is $186.62 and its 200-day simple moving average is $173.56. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The company had revenue of $155.74 million for the quarter, compared to analyst estimates of $155.38 million. During the same quarter in the previous year, the company earned $0.68 EPS. The firm’s revenue for the quarter was down 16.6% compared to the same quarter last year. Equities analysts anticipate that Repligen Co. will post 1.46 EPS for the current year.

Analysts Set New Price Targets

RGEN has been the topic of a number of research reports. KeyCorp raised their price target on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Stifel Nicolaus increased their price objective on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $196.70.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.